SAN
JUAN, Puerto Rico and LAUSANNE, Switzerland, July 12,
2024 /PRNewswire/ -- ImmuneAGE Bio raised
$2M and has built the first drug
discovery platform to rejuvenate the entire immune system at the
source: the hematopoietic stem cell (HSCs) residing in the bone
marrow. The platform allows for large-scale ex vivo
combinatorial drug screening for geroprotective cocktails of
rejuvenating therapeutics. ImmuneAGE achieve 1000x expansion of
HSCs, a factor of >70x more than prior efforts, allowing high
throughput drug discovery in HSCs for the first time.
ImmuneAge Bio is now advancing 3 programs:
IA-101, an oral small molecule immune booster targeting
respiratory infections and vaccine response in elderly
patients.
IA-201, an immune rejuvenation cocktail for ex vivo
use (on peripheral mobilized HSCs) targeting chemotherapy recovery
and bone marrow transplantation.
IA-301, an HSC expansion platform targeting bone marrow
transplantation as well as other immune cell types like T
cells.
ImmuneAGE is now raising a seed round.
'Immune Refresh Therapy'
Transplant of young bone marrow into aged mice can extend
lifespan by ±30% (largest lifespan effect size of any therapeutic
intervention tested to date). The entire immune system originates
from HSCs.
Management Team
Founder & CEO: Sebastian
Brunemeier, a longevity scientist by training. Previously
co-Founder and CIO of Cambrian Biopharma, Founder & COO of
Samsara Therapeutics, Principal at Apollo Health Ventures, General
Partner at Healthspan Capital. Formerly Oxford and University of Amsterdam.
COO: Josef Christensen, PhD,
Previously with McKinsey & Co focusing on pharma for 6 years,
Former Global Commercial Associate Director for Stem Cell Therapies
at Novo Nordisk, Former CBDO of StemMedical (second only company to
have gotten regulatory approval for mesenchymal stem
cell therapy in Europe),
former Partner at Apollo Health Ventures, PhD in Regenerative
Medicine and stem cell biology (Harvard & University of Copenhagen).
Scientific collaborators at the University
of Oxford (Dr Adam Wilkinson)
and University of Lausanne (Dr Nicola Vannini), research
operations led by Dr Stephan Emmrich
and Ryan Spangler.
Investors
Investors include 1517 Fund (Thiel Fellowship founders),
Infinita Fund, Emerging Longevity Ventures, VitaDAO, Healthspan
Capital, Balaji Srinivasan PhD (ex-a16z, The Network State),
Thomas Ebeling (Fmr CEO of Novartis,
board of Bayer and Lonza), Diane Seimetz PhD (Fresenius CSO &
Founder of Biopharma Excellence), Karl Pfleger PhD (Google AI,
longevity superangel), Alberto Santagostino (Head of Gene and Cell
Therapy at Lonza, fmr McKinsey partner), Jack O'Meara (Co-Founder of Ochre Bio), and
more.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immuneage-bio-launches-to-rejuvenate-the-immune-system-targeting-bone-marrow-stem-cells-302195874.html
SOURCE ImmuneAge Bio